Kythera Biopharmaceuticals

Sienna slumps as acne asset flunks phase 3 trials

The addition of the silver particle treatment to laser light therapy failed to improve outcomes against three key endpoints in two trials.

Nick Paul Taylor Jul 30, 2018 9:21am

JLABS alumnus Sienna guns for $75M IPO months after series B

Jul 6, 2017 4:25am

Ex-Kythera team raises $40M for dermatology clinical trials

Apr 25, 2017 5:04am

Kythera vets regroup around a $34M cosmetic biotech startup

Apr 29, 2016 9:54am